H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Dyne Therapeutics (DYN) to $60 from $46 and keeps a Buy rating on the shares. The DELIVER study data are a “clear win” and remove the safety overhang on the shares. The data demonstrate consistent functional superiority over the standard of care, the analyst tells investors in a research note. H.C. Wainwright believes DYNE-251 gas emerged as the presumptive next-generation leader for Exon 51, offering a “de-risked path” to an application filing in Q2 of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Reports Positive Phase 1/2 Trial Results
- Dyne Therapeutics reports ‘positive’ results from Phase 1/2 DELIVER trial
- Dyne Therapeutics price target raised to $21 from $12 at Bernstein
- Dyne Therapeutics price target lowered to $17 from $18 at JPMorgan
- Dyne Therapeutics price target lowered to $11 from $13 at Oppenheimer